ReviewCurrent medicinal chemistry2026
Ferroptosis and Its Crosstalk with Other Cell Death Modes in Ischemic Stroke.
Review in Current medicinal chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Ischemic stroke is the most common cerebrovascular disease. The core pathological mechanism underlying its neurological deficits is the massive neuronal death triggered by cerebral ischemia, hypoxia, and reperfusion injury following a sudden interruption of cerebral blood flow. Ferroptosis is a form of cell death characterized by iron overload, amino acid metabolism disorder, and lipid peroxidation, primarily occurring during organ ischemia-reperfusion. In recent years, with the clinical advancement of intravenous thrombolysis and endovascular thrombectomy, the incidence of ferroptosis in neurons after ischemic stroke has increased significantly. Importantly, substantial evidence indicates that ferroptosis not only directly damages neurons but also acts synergistically with other modes of cell death, further exacerbating brain tissue injury. Therefore, this review summarizes the mechanisms of ferroptosis following ischemic stroke, its role in neurological impairment, and explores the synergistic interactions between ferroptosis and other cell death pathways, which will provide an important theoretical foundation for the development of neuroprotective pharmacological therapies and innovative treatment strategies for ischemic stroke.
Indexed as
Identifiers
42381316What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.